INOVA Diagnostics Revenue and Competitors

Claim your profile

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • INOVA Diagnostics's estimated annual revenue is currently $47.1M per year.(i)
  • INOVA Diagnostics's estimated revenue per employee is $155,000

Employee Data

  • INOVA Diagnostics has 304 Employees.(i)
  • INOVA Diagnostics grew their employee count by -3% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.7M619%$53MN/A
#2
$34.3M17717%$110MN/A
#3
$0.4M2735%$236.7MN/A
#4
$34.5M178-5%$160MN/A
#5
$3.7M2420%N/AN/A
#6
$147.3M3212%$192.5MN/A
#7
$17.5M113-3%$24.1MN/A
#8
$2.7M4379%N/AN/A
#9
$34.1M220100%N/AN/A
#10
$47.1M304-3%N/AN/A

INOVA Diagnostics, Inc. was formed in 1987 by a group of scientists—drawn from the academic, clinical and industrial communities but united by one common interest... Autoimmune Disease Diagnostic Technology! INOVA's founders include research scientists who were directly involved in the early development of autoimmune disease serology as well as the people responsible for the first commercially available

keywords:N/A

N/A

Total Funding

304

Number of Employees

$47.1M

Revenue (est)

-3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

INOVA Diagnostics News

2022-04-20 - Antinuclear Antibody Testing Market Trends, Growth and ...

Antinuclear Antibody Testing Market Trends, Growth and Outlook 2022-2030| Key Players – Bio-Rad Laboratories, Inc., Inova Diagnostics, Inc.

2022-04-19 - Autoimmune Disease Diagnostics Market Size, Scope And ...

Siemens, Abbott, Thermo Fisher Scientific, Danaher, Bio-Rad Laboratories, GRIFOLS, Trinity Biotech, Inova Diagnostics, HYCOR Biomedical,...

2022-04-19 - Global Automated Microtiter Plate Processor Market 2022 ...

Significant Key merchants/industry producers include: Inova Diagnostics; Bio-Rad; AIKANG; Agilent; DAS.srl; Oyster Bay Pump Works; Diatron.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$102.6M30424%N/A
#2
$49.9M30716%N/A
#3
$105M3114%N/A
#4
$88.5M312N/AN/A
#5
$46.3M31421%$340.5M